During a live event, Carol Ann Huff, MD, and participants discussed real-world evidence and personal experiences with talquetamab in relapsed/refractory multiple myeloma.
Patients received an initial intratumoral injection of RP1 with up to 7 additional doses every 2 weeks, plus 240 mg nivolumab ...
Dr Danny Nguyen discusses the shift of clinical trials to community settings, the impact of AI in oncology, and the latest ...
Naomi Haas, MD, from the Hospital at the University of Pennsylvania, explains that most trials regarding neoadjuvant therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results